#65 Tony Keating - Co-Founder of ResApp

ResApp is a biotech company that commercialised technology to diagnose respiratory illnesses based on an audio recording of a patient’s cough on their phone. After proving immensely useful for diagnosing COVID-19 during the height of pandemic, Pfizer acquired the company for $180 million.

Throughout the episode, Tony discusses the path of listing on the ASX early-on and how that provided the initial capital needed for the company to succeed. Coming from a research background, Tony also talks about how his experience as a scholar and background in engineering contributes to being an effective CEO.

If you enjoy this episode, feel free to share with family and friends and leave a 5 star review.

Share the episode: https://thedionguagliardopodcast.buzzsprout.com/share

More on us!

Dion's Newsletter: http://eepurl.com/hHg1ff

Our social media: https://linktr.ee/FortressFinancial

Fortress Family Office: https://www.fortressfamilyoffice.com/

Contact us: admin@fortressfamilyoffice.com

Chapters

• 0:00 Highlight Clip
• 0:41 Introduction
• 2:09 Guest Background and Introduction
• 2:52 Why did Tony Keating List ResApp on the ASX
• 4:51 What is ResApp and The Journey So Far
• 7:11 Was Tony Keating Always Entrepreneurial?
• 10:47 What Advantages does Tony's Engineering Give Him as CEO
• 18:22 Who did Tony Keating Turn To in Times of Need?
• 19:13 Tony Keating's Biggest Strength and How it Helped Him Succeed with ResApp
• 19:39 What was the Biggest Learning Tony Keating had when Leading ResApp
• 22:35 Most Difficult Point for Tony Keating in the ResApp Journey
• 26:12 How Tony Keating Manged ResApp Staff Morale During Tough Times
• 30:15 The Best Advice Tony Keating was Given for ResApp
• 31:48 Tony Keating's Biggest Inspirations
• 33:20 The Business Books that Taught Tony Keating Success
• 35:54 Outtro